Castle Biosciences Presents New Data on Sentinel Lymph Node Positivity Prediction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Source: Newsfilter
- New Data Presentation: Castle Biosciences will present data on the DecisionDx-Melanoma's i31-SLNB test at the 2026 Society of Surgical Oncology Annual Meeting, aiming to predict sentinel lymph node positivity and further validate the test's significance in clinical decision-making.
- Clinical Validation Results: Initial study findings indicate that the test can impact sentinel lymph node biopsy decisions and identify low-risk metastatic patients, thereby optimizing patient management strategies in line with National Comprehensive Cancer Network risk thresholds.
- Personalized Risk Assessment: The i31-SLNB algorithm integrates the 31-GEP score with key clinicopathologic factors to provide a more precise risk estimation than staging alone, supporting personalized shared decision-making and enhancing patient treatment confidence.
- Broad Application Foundation: DecisionDx-Melanoma has been clinically validated in over 10,000 patient samples and has been ordered more than 220,000 times since launch, demonstrating its association with improved patient survival and highlighting its importance in managing cutaneous melanoma.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CSTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CSTL
Wall Street analysts forecast CSTL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.250
Low
41.00
Averages
47.20
High
52.00
Current: 20.250
Low
41.00
Averages
47.20
High
52.00
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Castle Biosciences Grants Restricted Stock Units to Employees
- Employee Incentive Program: On June 15, 2026, Castle Biosciences granted 204,925 restricted stock units (RSUs) to 172 employees as an inducement for their employment, highlighting the company's commitment to attracting talent.
- Grant Details: The RSUs were awarded under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% vesting on the first anniversary and the remainder in three equal annual installments, ensuring continued employee service.
- Company Background: Castle Biosciences focuses on diagnostics for dermatologic and gastroenterological diseases, aiming to improve patient care through innovative tests that enhance disease management and patient outcomes, showcasing its leadership in the healthcare sector.
- Market Impact: By implementing such incentive measures, Castle Biosciences not only boosts employee loyalty and engagement but also enhances its attractiveness and innovative capacity in a highly competitive healthcare market.
See More
Castle Biosciences Grants Restricted Stock Units to Employees
- Employee Incentive Program: On June 15, 2026, Castle Biosciences granted 204,925 restricted stock units (RSUs) to 172 employees as an inducement for their employment, reflecting the company's commitment to attracting and retaining talent.
- Grant Details: The RSUs were awarded under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% vesting on the first anniversary and the remainder in three equal annual installments.
- Long-term Service Commitment: Employees must continue their service through each vesting date to receive the shares, which not only enhances employee retention but also fosters a long-term partnership between the company and its workforce.
- Strategic Company Development: By implementing this incentive program, Castle Biosciences aims to boost employee motivation and loyalty, thereby driving innovation and competitiveness in the dermatologic and gastroenterological sectors.
See More
Castle Biosciences Surpasses 100,000 TissueCypher Test Orders
- Order Milestone: Castle Biosciences has surpassed 100,000 clinical test orders for its TissueCypher® Barrett's Esophagus Test, indicating robust growth in the personalized medicine sector and reflecting increasing market demand for precision healthcare solutions.
- Risk Assessment Capability: The TissueCypher test predicts a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, enabling clinicians to tailor management strategies based on individual risk profiles, thereby enhancing treatment outcomes for patients.
- Clinical Validation Support: The test has been studied in biopsies from over 8,000 patients and is backed by more than 17 peer-reviewed publications, demonstrating its unique advantages over traditional histopathological risk assessments and further solidifying Castle Biosciences' leadership in the diagnostics field.
- Improved Patient Experience: Patient Robin Byrd Wilfong received a low-risk result from TissueCypher, indicating only a 2% chance of progression over five years, which not only alleviated her anxiety but also empowered her to manage her health more effectively, highlighting the test's significance in providing psychological support to patients.
See More
Castle Biosciences to Present at 2026 Jefferies Global Healthcare Conference
- Conference Presentation: Castle Biosciences is scheduled to present a company overview at the 2026 Jefferies Global Healthcare Conference on June 3 at 1:20 p.m. Eastern time, showcasing its innovative testing solutions aimed at improving health and attracting investor interest.
- Live Webcast Availability: The presentation will be available via live audio webcast on Castle Biosciences' website, allowing real-time access for attendees, with a replay option provided post-event to ensure that key information reaches all interested investors.
- Company Background: Castle Biosciences focuses on diagnostics for dermatologic and gastroenterological diseases, developing personalized, clinically actionable solutions that enhance disease management and patient outcomes, highlighting its innovative capabilities and market potential in the healthcare sector.
- Brand and Products: The company boasts a range of trademarks and products, including the DecisionDx series, underscoring its leadership in molecular testing and personalized medicine, which further solidifies its market share and influence in the diagnostics industry.
See More
Castle Biosciences Wins Genomics Innovation Award for AdvanceAD-Tx Test
- Award Recognition: Castle Biosciences' AdvanceAD-Tx test has been awarded the 'Genomics Innovation Award' at the 10th annual MedTech Breakthrough Awards, marking the fifth time the company has received this honor, underscoring its leadership in advancing medical technology.
- Clinical Validation Success: The AdvanceAD-Tx test utilizes a non-invasive skin scraping method to evaluate 487 genes, guiding systemic treatment decisions for patients aged 12 and older with moderate-to-severe atopic dermatitis, significantly enhancing the personalization of treatment options.
- Patient Outcome Improvement: In a prospective multi-center validation study, patients treated in alignment with their AdvanceAD-Tx results were 5.5 times more likely to achieve near-clear skin and did so 3.8 times faster than those receiving alternative therapies, highlighting the test's critical role in clinical applications.
- Enhanced Industry Impact: This award reflects the growing global influence of the digital healthcare sector, as Castle Biosciences drives improvements in patient care and healthcare value through its innovative solutions.
See More
Castle Biosciences Reports Strong Q1 2026 Earnings with Raised Revenue Guidance
- Significant Revenue Growth: Castle Biosciences reported $83.7 million in revenue for Q1 2026, a 36% increase year-over-year, reflecting strong performance in core revenue drivers, which bolstered market confidence and prompted an upward revision of the 2026 revenue outlook to $345 million to $355 million.
- Increased Test Report Volume: The company delivered 10,021 test reports for DecisionDx-Melanoma in Q1, representing a 16% year-over-year growth, while TissueCypher reports surged from 7,432 in 2025 to 11,745, marking a remarkable 58% increase, indicating sustained demand for its products.
- Improved Gross Margin: The gross margin for Q1 2026 was 72.8%, significantly up from 49.2% in Q1 2025, showcasing substantial improvements in cost control and operational efficiency, although the adjusted gross margin slightly decreased to 75.6%.
- Cash Flow Position: As of March 31, 2026, Castle Biosciences had $261.7 million in cash, cash equivalents, and marketable securities; despite a net loss of $14.5 million in Q1, the company anticipates that future M&A activities will drive growth and enhance financial stability.
See More
Castle Biosciences Grants Restricted Stock Units to Employees
- Employee Incentive Program: On June 15, 2026, Castle Biosciences granted 204,925 restricted stock units (RSUs) to 172 employees as an inducement for their employment, highlighting the company's commitment to attracting talent.
- Grant Details: The RSUs were awarded under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% vesting on the first anniversary and the remainder in three equal annual installments, ensuring continued employee service.
- Company Background: Castle Biosciences focuses on diagnostics for dermatologic and gastroenterological diseases, aiming to improve patient care through innovative tests that enhance disease management and patient outcomes, showcasing its leadership in the healthcare sector.
- Market Impact: By implementing such incentive measures, Castle Biosciences not only boosts employee loyalty and engagement but also enhances its attractiveness and innovative capacity in a highly competitive healthcare market.
See More
Castle Biosciences Grants Restricted Stock Units to Employees
- Employee Incentive Program: On June 15, 2026, Castle Biosciences granted 204,925 restricted stock units (RSUs) to 172 employees as an inducement for their employment, reflecting the company's commitment to attracting and retaining talent.
- Grant Details: The RSUs were awarded under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% vesting on the first anniversary and the remainder in three equal annual installments.
- Long-term Service Commitment: Employees must continue their service through each vesting date to receive the shares, which not only enhances employee retention but also fosters a long-term partnership between the company and its workforce.
- Strategic Company Development: By implementing this incentive program, Castle Biosciences aims to boost employee motivation and loyalty, thereby driving innovation and competitiveness in the dermatologic and gastroenterological sectors.
See More
Castle Biosciences Surpasses 100,000 TissueCypher Test Orders
- Order Milestone: Castle Biosciences has surpassed 100,000 clinical test orders for its TissueCypher® Barrett's Esophagus Test, indicating robust growth in the personalized medicine sector and reflecting increasing market demand for precision healthcare solutions.
- Risk Assessment Capability: The TissueCypher test predicts a patient's five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, enabling clinicians to tailor management strategies based on individual risk profiles, thereby enhancing treatment outcomes for patients.
- Clinical Validation Support: The test has been studied in biopsies from over 8,000 patients and is backed by more than 17 peer-reviewed publications, demonstrating its unique advantages over traditional histopathological risk assessments and further solidifying Castle Biosciences' leadership in the diagnostics field.
- Improved Patient Experience: Patient Robin Byrd Wilfong received a low-risk result from TissueCypher, indicating only a 2% chance of progression over five years, which not only alleviated her anxiety but also empowered her to manage her health more effectively, highlighting the test's significance in providing psychological support to patients.
See More
Castle Biosciences to Present at 2026 Jefferies Global Healthcare Conference
- Conference Presentation: Castle Biosciences is scheduled to present a company overview at the 2026 Jefferies Global Healthcare Conference on June 3 at 1:20 p.m. Eastern time, showcasing its innovative testing solutions aimed at improving health and attracting investor interest.
- Live Webcast Availability: The presentation will be available via live audio webcast on Castle Biosciences' website, allowing real-time access for attendees, with a replay option provided post-event to ensure that key information reaches all interested investors.
- Company Background: Castle Biosciences focuses on diagnostics for dermatologic and gastroenterological diseases, developing personalized, clinically actionable solutions that enhance disease management and patient outcomes, highlighting its innovative capabilities and market potential in the healthcare sector.
- Brand and Products: The company boasts a range of trademarks and products, including the DecisionDx series, underscoring its leadership in molecular testing and personalized medicine, which further solidifies its market share and influence in the diagnostics industry.
See More
Castle Biosciences Wins Genomics Innovation Award for AdvanceAD-Tx Test
- Award Recognition: Castle Biosciences' AdvanceAD-Tx test has been awarded the 'Genomics Innovation Award' at the 10th annual MedTech Breakthrough Awards, marking the fifth time the company has received this honor, underscoring its leadership in advancing medical technology.
- Clinical Validation Success: The AdvanceAD-Tx test utilizes a non-invasive skin scraping method to evaluate 487 genes, guiding systemic treatment decisions for patients aged 12 and older with moderate-to-severe atopic dermatitis, significantly enhancing the personalization of treatment options.
- Patient Outcome Improvement: In a prospective multi-center validation study, patients treated in alignment with their AdvanceAD-Tx results were 5.5 times more likely to achieve near-clear skin and did so 3.8 times faster than those receiving alternative therapies, highlighting the test's critical role in clinical applications.
- Enhanced Industry Impact: This award reflects the growing global influence of the digital healthcare sector, as Castle Biosciences drives improvements in patient care and healthcare value through its innovative solutions.
See More
Castle Biosciences Reports Strong Q1 2026 Earnings with Raised Revenue Guidance
- Significant Revenue Growth: Castle Biosciences reported $83.7 million in revenue for Q1 2026, a 36% increase year-over-year, reflecting strong performance in core revenue drivers, which bolstered market confidence and prompted an upward revision of the 2026 revenue outlook to $345 million to $355 million.
- Increased Test Report Volume: The company delivered 10,021 test reports for DecisionDx-Melanoma in Q1, representing a 16% year-over-year growth, while TissueCypher reports surged from 7,432 in 2025 to 11,745, marking a remarkable 58% increase, indicating sustained demand for its products.
- Improved Gross Margin: The gross margin for Q1 2026 was 72.8%, significantly up from 49.2% in Q1 2025, showcasing substantial improvements in cost control and operational efficiency, although the adjusted gross margin slightly decreased to 75.6%.
- Cash Flow Position: As of March 31, 2026, Castle Biosciences had $261.7 million in cash, cash equivalents, and marketable securities; despite a net loss of $14.5 million in Q1, the company anticipates that future M&A activities will drive growth and enhance financial stability.
See More
